Clustering of acute and subacute stent thrombosis related to the introduction of generic clopidogrel

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 19, Issue 2, 2014, Pages 201-208

  Kovacic, Jason C ^a   Mehran, Roxana ^a   Sweeny, Joseph ^a   Li, Jennifer R ^a   Moreno, Pedro ^a   Baber, Usman ^a   Krishnan, Prakash ^a   Badimon, Juan J ^a   Hulot, Jean Sebastien ^a   Kini, Annapoorna ^a   Sharma, Samin K ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI HOSPITAL   (United States)

Author keywords

clopidogrel; generic; stent thrombosis

Indexed keywords

CLOPIDOGREL; GENERIC; STENT THROMBOSIS;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; CLUSTER ANALYSIS; DRUG SUBSTITUTION; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; REGISTRIES; STENTS; THROMBOSIS; TICLOPIDINE;

EID: 84894485986     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248413510605     Document Type: Article

References (39)

1. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006 ; 48 (12). 2584-2591
2. Machecourt J, Danchin N, Lablanche JM, et al. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: the EVASTENT matched-cohort registry. J Am Coll Cardiol. 2007 ; 50 (6). 501-508
3. Roy P, Bonello L, Torguson R, et al. Temporal relation between Clopidogrel cessation and stent thrombosis after drug-eluting stent implantation. Am J Cardiol. 2009 ; 103 (6). 801-805
4. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009 ; 302 (8). 849-857
5. Cayla G, Hulot JS, O'Connor SA, et al. Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. JAMA. 2011 ; 306 (16). 1765-1774
6. Finn AV, Joner M, Nakazawa G, et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation. 2007 ; 115 (18). 2435-2441
7. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006 ; 48 (1). 193-202
8. Kuchulakanti PK, Chu WW, Torguson R, et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation. 2006 ; 113 (8). 1108-1113
9. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005 ; 293 (17). 2126-2130
10. Kovacic JC, Lee P, Karajgikar R, et al. Safety of temporary and permanent suspension of antiplatelet therapy after drug eluting stent implantation in contemporary "real-world" practice. J Interv Cardiol. 2012 ; 25 (5). 482-492
11. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007 ; 357 (20). 2001-2015
12. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009 ; 361 (11). 1045-1057
13. Di Girolamo G, Czerniuk P, Bertuola R, Keller GA. Bioequivalence of two tablet formulations of clopidogrel in healthy Argentinian volunteers: a single-dose, randomized-sequence, open-label crossover study. Clin Ther. 2010 ; 32 (1). 161-170
14. Richter W, Erenmemisoglu A, Van der Meer MJ, Emritte N, Tuncay E, Koytchev R. Bioequivalence study of two different clopidogrel bisulfate film-coated tablets. Arzneimittelforschung. 2009 ; 59 (6). 297-302
15. Park YM, Ahn T, Lee K, et al. A comparison of two brands of clopidogrel in patients with drug-eluting stent implantation. Korean Circ J. 2012 ; 42 (7). 458-463
16. Shim CY, Park S, Song JW, Lee SH, Kim JS, Chung N. Comparison of effects of two different formulations of clopidogrel bisulfate tablets on platelet aggregation and bleeding time in healthy Korean volunteers: a single-dose, randomized, open-label, 1-week, two-period, phase IV crossover study. Clin Ther. 2010 ; 32 (9). 1664-1673
17. Lainesse A, Ozalp Y, Wong H, Alpan RS. Bioequivalence study of clopidogrel bisulfate film-coated tablets. Arzneimittelforschung. 2004 ; 54 (9A). 600-604
18. Setiawati E, Yunaidi DA, Handayani LR, Santoso ID, Setiawati A, Tjandrawinata RR. Bioequivalence study of two clopidogrel film-coated tablet formulations in healthy volunteers. Arzneimittelforschung. 2011 ; 61 (12). 681-684
19. Kim SD, Kang W, Lee HW, et al. Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. Clin Ther. 2009 ; 31 (4). 793-803
20. Doll J, Zeitler E, Becker R. Generic clopidogrel: time to substitute?. JAMA. 2013 ; 310 (2). 145-146
21. Jeong YH, Koh JS, Kang MK, et al. The impact of generic clopidogrel bisulfate on platelet inhibition in patients with coronary artery stents: results of the ACCEL-GENERIC study. Korean J Intern Med. 2010 ; 25 (2). 154-161
22. Gomez Y, Adams E, Hoogmartens J. Analysis of purity in 19 drug product tablets containing clopidogrel: 18 copies versus the original brand. J Pharm Biomed Anal. 2004 ; 34 (2). 341-348
23. FDA News Release. http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm304489.htm. Accessed April 18, 2013.
24. Facts About Generic Drugs. http://www.fda.gov/Drugs/ResourcesForYou/ Consumers/BuyingUsingMedicineSafely/UnderstandingGenericDrugs/ucm167991.htm. Accessed April 16, 2013.
25. Kovacic JC, Mehran R, Karajgikar R, et al. Female gender and mortality after percutaneous coronary intervention: Results from a large registry. Catheter Cardiovasc Interv. 2012 ; 80 (4). 514-521
26. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007 ; 115 (17). 2344-2351
27. Wade OL.. Digoxin 1785-1985. I. Two hundred years of digitalis. J Clin Hosp Pharm. 1986 ; 11 (1). 3-9
28. Jneid H, Anderson JL. Wright RS, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST- elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American college of cardiology foundation/american heart association task force on practice guidelines. J Am Coll Cardiol. 2012 ; 60 (7). 645-681
29. Scott SA, Sangkuhl K, Stein CM, et al. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013 ; 94 (3). 317-323
30. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010 ; 363 (20). 1909-1917
31. Wu H, Jing Q, Wang J, Guo X. Pantoprazole for the prevention of gastrointestinal bleeding in high-risk patients with acute coronary syndromes. J Crit Care. 2011 ; 26 (4). e1 - e6
32. Chen M, Wei JF, Xu YN, Liu XJ, Huang DJ. A meta-analysis of impact of proton pump inhibitors on antiplatelet effect of clopidogrel. Cardiovasc Ther. 2012 ; 30 (5). e227 - e233
33. Focks JJ, Brouwer MA, van Oijen MG, Lanas A, Bhatt DL, Verheugt FW. Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome- a systematic review. Heart. 2013 ; 99 (8). 520-527
34. El-Halabi MM, Zgheib N, Mansour NM, et al. CYP2C19 Genetic polymorphism, rabeprazole and esomeprazole have no effect on the anti-platelet action of clopidogrel. J Cardiovasc Pharmacol. 2013 ; 62 (1). 41-49
35. Schulz S, Schuster T, Mehilli J, et al. Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. Eur Heart J. 2009 ; 30 (22). 2714-2721
36. Wenaweser P, Daemen J, Zwahlen M, et al. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol. 2008 ; 52 (14). 1134-1140
37. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007 ; 356 (10). 998-1008
38. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007 ; 356 (10). 1020-1029
39. Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007 ; 370 (9591). 937-948